Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers July 29, 2015
Pharmacy Choice - News - U.S. Pharmaceutical Industry - July 29, 2015

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

7/29/15 - Ascendis Pharma A/S to Report Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone and Host Conference Call on Thursday, July 30, 2015 at 9:00 a.m. Eastern Time
A simultaneous webcast of the conference call will be available on the Investor Relations tab of the Ascendis Pharma website at About Ascendis Pharma A/S Ascendis Pharma is applying its innovative TransCon technology, which combines the benefits of prodrug and sustained release technologies, to develop a pipeline of...
7/29/15 - Blaze Bioscience Announces Open Enrollment for Phase 1 Clinical Trial of Tumor Paint BLZ-100 in Patients with Solid Tumor Cancers
By a News Reporter-Staff News Editor at Biotech Week Blaze Bioscience, the Tumor Paint Company , a biotechnology company focused on guided cancer therapy, announced expansion of its Phase 1 program into multiple additional tumor types. The study is currently active at Overlake Medical Center in Bellevue, WA under the direction of principal inve
7/29/15 - Bristol-Myers Squibb Secures FDA Approval of Daklinza [Manufacturing Close - Up]
Bristol-Myers Squibb Company reported that Daklinza, an NS5A replication complex inhibitor, has been approved by the U.S. Food and Drug Administration. According to a release from the company, this approval marks the first time patients with chronic hepatitis C virus genotype 3 have a 12- week, once-daily, all-oral treatment option. "The U.S. appr
7/29/15 - C2 Therapeutics Receives FDA 510(k) Clearance for the Coldplay Cryoballoon? Full and Swipe Ablation Systems
C2 Therapeutics, a privately held company founded to improve treatment of precursors to esophageal cancer, today announced US Food and Drug Administration 510 clearance for the Coldplay Cryoballoon? Full Ablation System and the Coldplay Cryoballoon? Swipe Ablation System. The clearance of Coldplay Cryoballoon Full and Swipe Systems is an imp
7/29/15 - Cambridge researchers and pharma in innovative new consortium to develop and study early stage drugs [Global Data Point]
The Consortium will connect academic and clinical researchers at the University of Cambridge, the Babraham Institute and the Wellcome Trust Sanger Institute with pharmaceutical companies Astex Pharmaceuticals, AstraZeneca and GlaxoSmithKline. Professor Tony Kouzarides from the University of Cambridge, who will head the Therapeutics Consortium and..
7/29/15 - CASI Pharmaceuticals Appoints Leading Oncology Experts To Newly Formed Clinical Advisory Board [Kuwait News Agency]
CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announced today the formation of a clinical advisory board. Abou-Alfa is an associate professor of
7/29/15 - Cempra Reports Second Quarter 2015 Financial Results and Provides Corporate Update
Cempra, Inc., a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today reported financial results for the quarter ended June 30, 2015 and provided an update on recent corporate developments. Two additional studies were presented on Cempra's ot
7/29/15 - Ciclofilin Pharmaceuticals' Lead Antiviral Drug Reduces Liver HBV DNA [Khaleej Times (United Arab Emirates)]
-Ciclofilin Pharmaceuticals Inc., a hepatitis B virus drug developer, announced today its lead antiviral drug candidate demonstrated significantly reduced liver HBV DNA in a transgenic mouse model. The study was conducted by the National Institute of Allergy and Infectious Diseases, one of the centers within the National Institutes of Health.
7/29/15 - Conatus Pharmaceuticals to Report Second Quarter 2015 Financial Results
Conatus Pharmaceuticals Inc., a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that it will report financial results for the second quarter ended June 30, 2015, after the market close on Wednesday, August 5, 2015. Conatus will host a conference call and audio webca
7/29/15 - Corium Announces Positive Topline Results From Phase 2a Study of Transdermal MicroCor(R) PTH in Post-Menopausal Women [National News Agency (Lebanon)]
-Corium International, Inc., a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced positive topline interim results from its Phase 2 a study designed to determine the pharmacokinetics, pharmacodynamics and safety and tolerability of its...
7/29/15 - CytoDyn Completes Qualification of PRO 140 Material for Phase 3
CytoDyn Inc., a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus infection, today announced that the Company's QA/QC expert, Dr. Robert Schiff, has approved for release inventory suitable to satisfy CytoDyn's current Phase 3 trial. Nader Pourhassan, President and CEO, commented: "We are
7/29/15 - Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients
PARSIPPANY, N.J. and BERKELEY, Calif., July 29, 2015/ PRNewswire/ Daiichi Sankyo, Inc. and Plexxikon Inc., a member of the Daiichi Sankyo Group, announced today that The New England Journal of Medicine published clinical trial results demonstrating that the investigational drug, PLX3397, an oral targeted CSF-1R inhibitor, induced prolonged tumor
7/29/15 - Daily Mail, London, market report column [Daily Mail, London]
Generic drugs maker Hikma Pharmaceuticals jumped 241 p to 2321 p as analysts applauded its pounds sterling 1.7 bn acquisition of Roxane Laboratories, the US generic drugs arm of Germany's Boehringer Ingelheim, making it the sixth largest company by revenue in the US generics market. It follows Teva's pounds sterling 26 bn purchase of Allergan's gen
7/29/15 - Easton Pharmaceuticals Announces the Appointment of Evan Karras as CEO / Director and Mr. Nunzio Valerie as President / CFO; Mr. Karras Possesses a Strong Background in Canadian and International Commercial Successes and Is Expected to Make Major Imp
Easton Pharmaceuticals Inc. announces the appointment of Evan Karras as CEO& Director and announces Mr. Easton Pharmaceuticals is pleased to announce the appointment of highly successful businessman, Evan Karras as CEO& Director, replacing Carla Pepe, who will assume the role of Secretary and Director. Mr. Karras stated, "Timing is everything, and
7/29/15 - FDA approves non-surgical temporary balloon device to treat obesity
Release date- 28072015- The U.S. Food and Drug Administration today approved a new balloon device to treat obesity without the need for invasive surgery. The ReShape Integrated Dual Balloon System is intended to facilitate weight loss in obese adult patients. 'For those with obesity, significant weight loss and maintenance of that weight loss often
7/29/15 - Ferring Pharmaceuticals moves forward with early stage development of bacteriophage therapy for inflammatory bowel disease
By a News Reporter-Staff News Editor at Biotech Week Ferring Pharmaceuticals announced that it will collaborate with Baltimore- based Intralytix, Inc. in the latest phase of its early stage development programme for a bacteriophage-based therapy for inflammatory bowel disease. To explore the possibility that bacteriophages could be used to combat
7/29/15 - First made-in-Singapore cancer drug enters clinical testing
By a News Reporter-Staff News Editor at Biotech Week SingaporeA made-in- Singapore cancer drug has advanced into clinical trials, charting a milestone in Singapore's biomedical sciences initiative that will go towards improving the lives of cancer patients in Singapore, and worldwide. This is the first publicly-funded drug candidate discovered
7/29/15 - Flexion Therapeutics Completes Enrollment in Phase 3 Clinical Trial With Lead Compound FX006 in Patients With Osteoarthritis of the Knee
Flexion Therapeutics, Inc. today announced that it has completed enrollment of 486 patients in the Phase 3 clinical trial of its lead compound FX006 approximately three months earlier than anticipated, and the company now plans on reporting topline data from this trial in the first quarter of 2016. This study will complete the requisite clinical
7/29/15 - Foundation Medicine Announces 2015 Second Quarter Results and Recent Highlights
Foundation Medicine, Inc. today reported financial and operating results for its second quarter ended June 30, 2015. Foundation Medicine reported total revenue of $22.5 million in the second quarter of 2015, compared to $14.5 million in the second quarter of 2014 and $19.3 million in the first quarter of 2015. Revenue from clinical testing in the s
7/29/15 - Galapagos' selective JAK1 inhibitor filgotinib meets key efficacy endpoints, shows ACR70 responses up to 39%, and maintains safety profile after 24 weeks of treatment in DARWIN 1 Phase 2B study
Galapagos NV announced today that at week 24, patients treated with the selective JAK1 inhibitor filgotinib showed further improvement in signs and symptoms of rheumatoid arthritis activity, as demonstrated by improved ACR responses, DAS28, and other scores, compared to week 12 in the DARWIN 1 Phase 2 B methotrexate add-on study. In this study, f
7/29/15 - Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review
Naloxone nasal spray is expected to be the first FDA- approved intranasal naloxone product indicated to treat opioid overdose in the United States. "As the rate of opioid overdoses and their profound impact on communities nationwide continues to rise, naloxone nasal spray may help make every life-saving second count by potentially allowing anyone-
7/29/15 - Intercept to Report Second Quarter 2015 Financial Results on August 5 and Present at Upcoming Conferences
Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic underserved liver diseases, such as primary biliary cirrhosis and nonalcoholic steatohepatitis, today announced that it will report second quarter 2015 financial results after the...
7/29/15 - KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia
KaloBios Pharmaceuticals, Inc., a monoclonal antibody company focused on developing innovative therapies to benefit patients with diseases of unmet medical need, with a focus on oncology, announced today that the U.S. Food and Drug Administration has cleared the company's investigational new drug application for KB003, an anti-GM-CSF monoclonal a
7/29/15 - Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Submits NDA To FDA For Narcan (naloxone) Nasal Spray
Lightlake Therapeutics Inc., a specialty pharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that Adapt Pharma Limited, Lightlake's partner for treating opioid overdose with intranasal naloxone, has submitted a New Drug Application to the U.S. Food and Drug Administration for Narcan
7/29/15 - Marin: Drug firms must pay for pill disposal [The Marin Independent Journal, Novato, Calif.]
July 29 Marin County officials launched a new front in the war on prescription drug abuse Tuesday, saying pharmaceutical firms should pay for the safe disposal of old pills and medications. A spokeswoman for the California Retailers Association pledged cooperation. The board agreed with Supervisor Katie Rice, who called the measure a model of col
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

© 2015 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Pharmacy Spanish
This lesson is supported by:
Hands on Spanish
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement